main content start

Pagina inicial

Continue Watching

Últimos vídeos

Últimos vídeos

Brightcove Home Latest Listing

Oncology

Oncology

Brightcove Cards Listing

Hematology

Hematology

Brightcove Cards Listing

Popular em MedEnrich

Popular em MedEnrich

Popular in Sem nome
  • Myelodysplastic Syndromes23m 43s

    Desenvolvimento e Atualizações na Biologia das Mielodisplasias

    Desenvolvimento e Atualizações na Biologia das Mielodisplasias (MDS)
    síndromes mielodisplásicas mds avanços na biologia terapias inovadoras epidemiologia da mds
  • Oncospecials15m 30s

    A Relevância dos Agentes TKI na era das imunoterapias para o tratamento do carcinoma de células Renais

    ONCOPLUS apresenta: vídeo-aula com Dr. Denis Jardim na patologia de carcinoma de células renais.
    oncologia ccr câncer renal tki sunitinibe
  • Mieloma múltiplo9m 20s

    Integrating Pomalidomide Based Regimens in Multiple Myeloma

    Integrating pomalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (RRMM) involves using them as a core regimen, often combined with other agents like bortezomib or monoclonal antibodies for enhanced efficacy.
    pomalidomide-dexamethasone rrmm management progression-free survival combination therapies
  • Transplant15m 53s

    Profilaxia de CMV em receptores de transplantes

    Conheça as estratégias de profilaxia de CMV no pós-transplante de órgãos sólidos, melhor forma de manejo e monitorização de viremia.
    cmv hospitalar valganciclovir antiviral manejo de viremia transplante
  • Mieloma múltiplo10m 40s

    Recommendations -Management of Myeloma Related Renal Impairment

    Supportive Care, Mechanical Approach and Systemic Antimyeloma treatment are 3 pillars of management of Myeloma related renal impairment. In supportive care prompt initiation of high fluid administration, appropriate use of Bisphosphonates can help.
    myeloma renal impairment lancet guidelines
  • Mieloma múltiplo7m 42s

    MRD Assesment in Multiple Myeloma -Ready for Prime Time

    Multiple Myeloma is an incurable disease with patients relapsing even after achieving deep responses. Minimal Residual Disease (MRD) represents a relatively new way of evaluating response to treatment.
    minimum residual disease (mrd) mrd negativity multiple myeloma
  • Myelodysplastic Syndromes14m 13s

    ASH 2022 Update on Myelodysplastic Syndromes

    ASH 2022 - Update on Myelodysplastic Syndromes
    low risk mds venetoclax viale -a eln classification low dose lenalidomide tags: azacitidine
  • Câncer de próstata11m 38s

    Treatment Intensification in Metastatic Castration Sensitive Prostate Cancer

    PEACE-1 clinical trial demonstrated that combining ADT and docetaxel with abiraterone acetate plus prednisone (AAP) improves both overall survival (OS) and radiographic progression-free-survival (rPFS) in men with de novo mCSPC.
    treatment intensification mhspc triplet therapy peace-1 clinical trial
  • Acute Myeloid Leukaemia12m 22s

    EHA 2022 Updates : AML

    EHA Updates AML : QuANTUM phase 3 study showed significant overall survival in adults having FLT3-ITD+ acute myeloid leukaemia with  addition of quizartinib to standard induction and consolidation therapy alone.
    aml decitabine g-csf hypomethylating agents
  • Oncospecials6m 24s

    2nd Genenration TKIs for 1st line CP-CML -Selecting Right Patients

    Deep Molecular Responses (DMR) in CML can protect from progression.2nd generation TKIs are associated with higher rates of DMR than 1st generation TKIs.
    2nd generation tki deep molecular response elts high risk e14a2 transcripts

Webinar passado

Webinar Cards Listing

MedBytes

MedBytes

Medbytes Cards Listing
Hola, ¿puedo ayudar?
Suporte por bate-papoX
Equipe de suporte
Hola, ¿cómo puedo ayudarlo hoy?
Seleccione una de las siguientes opciones.

Buscar información

No puedo iniciar sesión o registrarse

compartilhar comentarios